Medical need, scientific opportunity and the drive for antimalarial drugs

By R. Ridley. Nature, 2002

792 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Antimalarial drug discovery: efficacy models for compound screening (2004, background): “falciparum malaria should be efficacious against drug-resistant strains, provide cure within a reasonable time (ideally three days or less) to ensure good compliance, be safe, be suitable for small children and pregnant women, have appropriate formulations for oral use and, above all, be affordabl”
The Transcriptome of the Intraerythrocytic Developmental Cycle of Plasmodium falciparum (2003, background): “strains resistant to the mainstays of antimalarial treatment (”
Engineering a mevalonate pathway in Escherichia coli for production of terpenoids (2003, background): “Artemisinins have been acclaimed as the next generation of antimalarial drugs because they show little or no cross-resistance with existing antimalarial”
In vitro antiplasmodial activity of medicinal plants native to or naturalised in South Africa. (2004, background): “Although a number of advances have been made towards the understanding of the disease, relatively few antimalarial drugs have been developed in the last 30 years (Ridley, 2002).”